Vagal Nerve Stimulation Assessed by the Diving Reflex: An Investigation Into Mechanisms of Asthma Death
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Yorkshire
-
Cottingham, Yorkshire, United Kingdom, HU16 5JQ
- Hull Clinical Trials Unit, Respiratory academic department
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Syncopal Asthmatics: Asthmatic patients with a history of syncope during asthma exacerbations
- Normal Asthmatics: Asthmatic patients on BTS Step 3 treatment (LABA/ICS) with no history of syncope during exacerbations
- Normal volunteers: no history of airways disease or syncope
Exclusion Criteria:
• Subjects who are pregnant, or have pacemakers in situ are excluded from this study.
- Subjects with significant cardiovascular disease are excluded from this study.
- Those who are non-English speakers and special groups (i.e. mentally ill, children under 16 years of age, and those suffering from dementia) will be excluded.
- No test will be performed on any subject during an acute worsening of asthma or upper airway infection. If the subject has had an upper airway infection in the last three weeks. Another appointment should be made unless the subject is unwilling to come back, in which case testing should continue. The number of days elapsed since the end of the airway infection should be recorded.
- If the subject smokes: citric acid or capsaicin challenges must be performed at least one hour after the last cigarette has been smoked.
- Subjects taking beta-blockers and calcium antagonists will be excluded from this study. No beta agonists should be taken within 6 hours of starting this study.
- If the subject has taken any over the counter (OTC) cough mixture within the last twelve hours: If the subject is willing to come back another time for challenge testing, another appointment should be made. If the subject is unwilling to return another time, testing should proceed and the medication used recorded.
- If the subject has had any food or drink products containing caffeine or menthol within the last hour. If the subject is unwilling to wait for 1 hour before starting the test, the subject should return another time. If the subject is unwilling to return another time, testing should proceed and the medication used recorded.
- If the participant is currently involved in research, or within 3 months of participation in any type of research, they will be excluded from this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Syncopal Asthmatic
All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
|
All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
|
|
Experimental: Non Syncopal Asthmatic
All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
|
All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
|
|
Experimental: Normal Volunteers
All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
|
All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in heart rate from baseline
Time Frame: 2 minutes prior to facial immersion in water and in 10 second epochs continuously until 3 minutes after facial immersion
|
Nexfin and ECG monitoring continuously measuring subject heart rate during dive protocol, over a period of 6 minutes.
Beat to beat data is converted into mean HR per 10-second epoch and compared to a baseline value for each subject.
|
2 minutes prior to facial immersion in water and in 10 second epochs continuously until 3 minutes after facial immersion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood pressure from baseline
Time Frame: 2 minutes before facial immersion and continuously throughout dive protocol, over a period of 6 minutes
|
Nexfin monitoring continuously measuring subject blood pressure (systolic, diastolic and mean arterial pressure) during dive protocol, over a period of 6 minutes.
Beat to beat data is converted into mean blood pressure values per 10-second epoch and compared to a baseline value for each subject
|
2 minutes before facial immersion and continuously throughout dive protocol, over a period of 6 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alyn Morice, MD, Head Cardiorespiratory Studies Hull York Medical School University of Hull Castle Hill Hospital Cottingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Unconsciousness
- Consciousness Disorders
- Asthma
- Syncope
Other Study ID Numbers
Other Study ID Numbers
- CTU070813
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.